Table 1.
Population characteristics by CYP2C9 (rs1057910, rs1799853) and VKORC1 (rs9923231) genotypes in two study cohorts: 790 men from the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) (Screening cohort) and 1,436 prostate cancer patients treated at Tampere University Hospital (Hospital cohort) who had diagnosis of prostate cancer and genotypic information of all three investigated SNPs. There were no statistical differences between genotype groups in any of the variables. *None of the subjects were homozygous variant for all SNPs, however, 22 subjects were homozygous carrier for the CYP2C9 SNPs, and 112 for the VKORC1 SNPs.
Table 2.
Risk of overall death, cancer death, and prostate cancer (PCa)-specific death among carriers of warfarin dosing-related SNPs in two study cohorts: CYP2C9 SNPs rs1057910 and rs1799853 status were available for 790 and 1437 subjects in the Screening and Hospital cohorts, respectively. Information of VKORC1 SNP rs9923231 status was available for all study subjects (n = 810 (Screening cohort) and n = 1527 (Hospital cohort)). SNP status in analysis where all SNPs were combined included subjects with any SNPs (hetero- or homozygous) in investigated genes. Ref = reference.
Fig 1.
Risk of prostate cancer (PCa)-specific death, cancer death, and overall death among carriers of warfarin dosing-related SNPs in two study cohorts, the Finnish Randomized Study of Screening for Prostate Cancer (Screening cohort) and the Tampere University Hospital cohort (Hospital cohort).
Data are presented as hazard ratios (HR) with 95% confidence intervals (CI).
Table 3.
Warfarin use by CYP2C9 and VKORC1 genotype in a study cohort of prostate cancer patients from the Finnish Randomized Study of Screening for Prostate Cancer. CYP2C9 SNPs rs1057910 and rs1799853 status were available for 790 and VKORC1 SNP rs9923231 status for all study subjects (n = 810).
Table 4.
Risk of overall death, cancer-specific death, and prostate cancer (PCa)-specific death by warfarin use in a population stratified by warfarin dosing SNP genotypes. Analysis was limited to screening cohort. Non-warfarin users were used as the reference group. Data is expressed as hazard ratios with 95% confidence intervals. - = number of participants with minor alleles was too low for analysis. SNP status in analysis where all SNPs were combined included subjects with any SNPs (hetero- or homozygous) in investigated genes. *p < 0.05.
Fig 2.
Risk of prostate cancer (PCa)-specific death, cancer-specific death, and overall death by warfarin use in a population stratified by warfarin dosing SNP genotypes.
Analysis was limited to screening cohort. Non-warfarin users were used as a reference group. Data is expressed as hazard ratios with 95% confidence intervals.